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Edited by Maurice MontalAbstract Botulinum neurotoxin (BoNT) is the most toxic spe-
cies known to humans and has been identiﬁed as a potential biot-
errorist threat. Unfortunately, the only existing countermeasures
for BoNT intoxication involve vaccinations that are only eﬀec-
tive prior to entry of the toxin into neuronal cells. Herein, we dis-
close the ability of the micronutrient riboﬂavin (vitamin B2) to
photooxidatively inactivate BoNT in cell-based assays without
the need for toxin and riboﬂavin pre-exposure. In total, this
study suggests that botulism neurotoxicity may be blunted with
photodynamic therapy technology.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The naturally occurring botulinum neurotoxins (BoNTs) are
classiﬁed as the most lethal known poisons aﬀecting humans
and have become a considerable bioterrorism threat due to cer-
tain characteristic properties including relative ease of produc-
tion, extreme potency, and extended duration of paralytic
activity [1]. The anaerobic spore-forming bacterium Clostrid-
ium botulinum produces seven antigenically distinct serotypes
(A–G), which are ultimately responsible for the severe disease
botulism. Most commonly, botulism is caused by the con-
sumption of foods contaminated with one of these potent tox-
ins. Serotypes A, B, E, and F are responsible for human
intoxication, whereas C and D cause botulism in animals.
BoNT A is the deadliest of the seven toxins with a potency
approximately one million times greater than cobra toxin
and one hundred billion times greater than cyanide [2]; the
lethal dose (LD50) for a 70 kg human is estimated to be
0.70–0.90 lg by inhalation [3]. BoNT acts on the peripheral
nervous system by inhibiting the release of acetylcholine at
neuromuscular junctions resulting in progressive ﬂaccid paral-
ysis [4]. Structurally, BoNT A is a 150 kDa protein consisting
of a heavy-chain (100 kDa) and a disulﬁde bond-linked light-
chain (50 kDa). Once internalized into a cell, the light-chain
acts as a zinc-dependent protease, cleaving intracellular pro-
teins and culminating in paralysis.
BoNT is classiﬁed by the CDC as a category A agent which
includes those biological threats of the highest priority to the*Corresponding author. Fax: +1 858 784 2595.
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drugs approved for the treatment of botulism. Existing coun-
termeasures for botulism are limited to passive administration
of antibodies elicited against toxoid structures [5]. Unfortu-
nately, these vaccines are not available to the general public
due to the time and cost necessary to produce large quantities
needed in the event of a bioterrorist attack. More recent eﬀorts
have been focused on the development of non-toxic recombi-
nant vaccines consisting of BoNT fragments that elicit protec-
tive immune responses [5,6]. Currently, the CDC distributes
two equine antitoxins for treatment of adult botulism.
Although broadly eﬀective, administration of equine antibod-
ies can cause adverse reactions, such as serum sickness and
anaphylaxis [7]. Additionally, antitoxins are capable of only
sequestering freely circulating BoNT and consequently become
useless once the toxin has entered neuronal cells [8]. It is crit-
ical to note that the onset of botulism is very rapid with symp-
toms appearing as soon as 2 h after ingestion of contaminated
food [9], and that eﬀects attributable to BoNT intoxication can
continue up to 6 months [10]. Thus, therapeutic approaches
dependent on extracellular interaction with BoNT (e.g., anti-
bodies) have a very short window of application, limiting their
clinical utility. Due to the long paralysis and necessity for
intubation and mechanical respiration, the development of a
practical, cost-eﬀective, and easily obtainable postexposure
prophylaxis is essential for the treatment of botulism. In this
context, we now disclose the ability of the common micronutri-
ent riboﬂavin (vitamin B2) to photochemically prevent cellular
BoNT intoxication.2. Materials and methods
2.1. General methods
PC12 (rat adrenal pheochromocytoma) cells were purchased from
ATCC (CRL-1721) and grown on collagen coated tissue culture plates
in RPMI medium 1640 (Gibco) containing 2 mM L-glutamine, 10 mM
HEPES, 1.5 g/l sodium bicarbonate, 1.0 mM sodium pyruvate, 10% fe-
tal bovine serum, and 5% horse serum. Neuro-2a (murine cholinergic
neuroblastoma) cells were purchased from ATCC (CCL-131) and
grown on tissue culture plates in minimum essential medium with Ear-
les salt containing 2 mM L-glutamine, 1.5 g/l sodium bicarbonate,
0.1 mM non-essential amino acids, 1.0 mM sodium pyruvate, and
10% fetal bovine serum. Both cell lines were grown at 37 C in an
atmosphere of 5% CO2 and 95% air.
2.2. Cell-based assay
Initially, the cells were grown in a 75 cm2 ﬂask to 70–80% conﬂu-
ence. These cells were used to seed a 24-well plate at 0.9–1.0 · 105
cells per well and grown for 48 h. Then, the media was removed, re-
placed with serum-free media and the cells were grown for an addi-
tional 24 h. Next, the media was removed, replaced with serum-freeblished by Elsevier B.V. All rights reserved.
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(Metabiologics, Inc.), and incubated for 48 h. Finally, the cells were
harvested by removing the media, adding 75–90 ll of NuPAGE LDS
sample buﬀer (Invitrogen) diluted 1:3 with H2O followed by boiling
for 10 min.
2.3. Western blot analysis
Samples (20 ll) were run on a 12% Bis-Tris NuPAGE gel in MOPS-
SDS running buﬀer (Invitrogen) and transferred to a 0.2 lm nitrocel-
lulose membrane for 90–150 min at 30 V. The membrane was blocked
with 2% skim milk for 20 min at rt with gentle shaking followed by
washing 3 · 5 min at rt with gentle shaking (wash buﬀer: Tris-buﬀered
saline adjusted to contain 0.1% Tween-20). The primary antibody,
anti-SNAP-25 mouse monoclonal IgG1 (Santa Cruz Biotechnology,
200 lg/ml), was diluted 1:1000 into 2% skim milk and incubated for
20 min at rt with gentle shaking followed by washing 4 · 5 min at rt
with gentle shaking. The secondary antibody, goat anti-mouse HRP-
conjugated (Pierce, 10 lg/ml), was diluted 1:500 into 2% skim milk
and incubated for 1 h at rt with gentle shaking followed by washing
for 90 min at rt with gentle shaking (buﬀer exchange at 5, 10, 15, 30,
45, and 60 min). Bands were visualized using 4 ml of SuperSignal West
Dura Chemiluminescent Substrate (Pierce) and analyzed with a Fluor-
Chem 8900 imager (Alpha Innotech).3. Results and discussion
Proteins are one of many biological molecules sensitive to
photooxidation by ﬂavins [11]. Upon photoactivation with vis-
ible light, ﬂavins produce singlet oxygen ð1O2Þ and superoxide
ðO2 Þ, two compounds with potent reactivity towards biomol-
ecules [12]. Previous studies have reported that BoNT photo-
oxidation with the non-native sensitizer methylene blue leads
to a reduction of toxicity in vivo, attributable to a modiﬁcation
of critical tryptophan residues in the reactive domains of the
toxin [13–15]. While methylene blue has some clinical relevance
[16,17], we were interested in exploring natural dietary com-
pounds as potential inhibitors of BoNT toxicity. In this con-
text, we hypothesized that irradiation of BoNT in the
presence of riboﬂavin, or vitamin B2, would result in oxidation
of the toxin, leading to inactivation by either disruption of the
folded conformation and/or loss of catalytic activity.
Riboﬂavin 1 (Fig. 1) is an easily absorbed, water-soluble
micronutrient and photosensitizer that is obtained from die-
tary sources. Based upon the photochemical potential of ribo-
ﬂavin, we speculated that 1 would be an appropriate
photosensitizer and could both intra- and extracellularly oxi-
dize BoNT A. A critical feature of our selection of riboﬂavin
as a sensitizer resides in the fact that there are no known toxic
side eﬀects associated with large doses of this cell-permeant
vitamin. Thus, we felt that any concern of non-speciﬁc damage
to native cellular proteins from riboﬂavin irradiation would be
minimized. The ability of a potential treatment to functionFig. 1. Structure of riboﬂavin 1 (vitamin B2).once toxin translocation has occurred is an enormous
advantage over the use of either antitoxins or antibodies (i.e.,
pre-exposure prophylaxis) as these agents simply bind and
neutralize circulating toxin. Additionally, a therapeutic drug
such as 1 would be eﬀective against all BoNT serotypes, unlike
current therapies that are only speciﬁc for one or two serotypes.
In order to determine the ability of 1 to photooxidatively
protect against BoNT A intoxication, a cell-based assay was
conducted using two diﬀerent cell lines, PC12 and Neuro-2a.
The intracellular target of BoNT A protease within the neu-
roexocytosis apparatus is the soluble NSF-attachment protein
receptor (SNARE protein), SNAP-25 (synaptosomal-associ-
ated protein of 25 kDa). The BoNT A protease cleaves the
C-terminal nine amino acid residues of SNAP-25, thereby pro-
ducing an approximately 24 kDa degradation protein [18].
Analytical techniques have been developed that directly assess
SNAP-25 cleavage in cell lysates using immunoelectrophoresis
[19]. Using this method, we analyzed the amount of intact ver-
sus cleaved SNAP-25 allowing correlation to BoNT A activity
within the cell.
Our initial studies incorporated a preincubation step of
BoNT and 1, similar to previous reports of BoNT inhibitors
[20]; these experiments were utilized to optimize the concentra-
tion of 1 and irradiation time necessary to neutralize the toxic
eﬀects of BoNT A in PC12 cells. Here, a mixture of 1 (0, 1, 5,
25, 75, or 150 lM) and BoNT A (5 lg) was irradiated on a
white light transilluminator (3.4 mW/cm2) for 12 h at 4 C.
The reaction mixture was then diluted into cell culture media
and added to PC12 cells. After incubation for 48 h at 37 C,
the amount of cleaved SNAP-25 was determined by Western
blot analysis. At [1] >5 lM, no cleavage of SNAP-25 could
be observed, indicating complete toxin protection. In a second
study, the concentration of 1 was held constant and the irradi-
ation time was varied from 1 to 12 h (Fig. 2). A mixture of 1
(10 lM) and BoNT A (5 lg) was irradiated for 1, 6, or 12 h
at 4 C followed by the described cellular assay. After 6 h of
irradiation, SNAP-25 was fully intact (Fig. 2, lanes 5 and 6)
and importantly, even after 1 h, the majority of the SNAP-
25 was still uncleaved (Fig. 2, lanes 7 and 8) compared to po-
sitive controls containing BoNT A alone (Fig. 2, lane 2).
While PC12 cells have served as a model system for neuro-
biological and neurochemical studies, they are derived from
adrenal pheochromocytoma cells [21] and cannot fully mimic
the in vivo condition with respect to BoNT sensitivity. There-
fore, a second set of experiments was conducted with a neuro-
nal cell line (Neuro-2a) that is inherently more sensitive to
BoNT A toxicity [22]. Based on the initial PC12 data, further
studies were carried out at a concentration of 1 (10 lM) that
was fully protective after 6 h of irradiation. Riboﬂavin
(10 lM) and BoNT A (2.5 lg) mixtures were irradiated forFig. 2. Riboﬂavin protection against BoNT A in PC12 cells. Mixtures
of 1 (10 lM) and BoNT A (5 lg) were irradiated for 12 h (lanes 3 and
4), 6 h (lanes 5 and 6) and 1 h (lanes 7 and 8) in PBS at 4 C. Control
reactions contained buﬀer (lane 1) or BoNT A (lane 2) irradiated for
12 h. Following irradiation, reactions were diluted into cell culture
media and added to PC12 cells at 37 C. SNAP-25 cleavage was
analyzed as described.
Fig. 3. (A) Riboﬂavin protection against BoNT A in Neuro-2a cells.
Mixtures of 1 (10 lM) and BoNT A (2.5 lg) were irradiated for 1 h
(lane 5), 2 h (lane 6), 3 h (lane 7) and 6 h (lane 8) in PBS at 4 C.
Control reactions were irradiated for 6 h containing buﬀer (lane 1), 1
(lane 2), or BoNT A (lane 3). A dark control contained both 1 and
BoNT A (lane 4). (B) Quantitation of the western blot shown in (A) as
determined by densitometric analysis.
Fig. 4. Addition of 1 and BoNT A directly to Neuro-2a cells. (A)
Lanes: 1 and 2, no BoNT A or 1; 3 and 4, BoNT A (1.0 lg); 5 and 6, 1
(10 lM); 7 and 8, BoNT A (1.0 lg) and 1 (10 lM). Lanes 1, 3, 5, and 7
were incubated at 37 C in the dark for 48 h. Lanes 2, 4, 6, and 8 were
irradiated for 4 h at 37 C followed by incubation for an additional
42 h in the dark. (B) Quantitation of the Western blot shown in (A) as
determined by densitometric analysis.
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(Fig. 3). In the absence of 1, SNAP-25 is fully cleaved and ap-
pears as a single band at approximately 24 kDa (Fig. 3A, lane
3). After only 1 h of irradiation, intact SNAP-25 is visible
(Fig. 3A, lane 5) and after 6 h of irradiation a substantial
amount of SNAP-25 remains (Fig. 3A, lane 8). Critically, 1
provides no protection against BoNT A in the absence of a
light source (Fig. 3A, lane 4), giving credence to our hypothesis
that the protection results from reactive oxygen species gener-
ated by 1 photosensitization. Furthermore, gel electrophoresis
analysis of BoNT before and after irradiation in the presence
of 1 revealed that inactivation is likely to occur from destabi-
lization of the protein structure, rather than proteolysis of the
toxin (data not shown).
Encouragingly, the above ﬁndings demonstrate that the tox-
icity of BoNT A can be diminished by photooxidation. From
the perspective of botulism treatment and possible clinical
advancement, a more pertinent issue is whether or not this
holds true when BoNT A and photosensitizer are added di-
rectly to cells as in vivo preincubation of toxin and 1 would
be impractical for treating BoNT intoxication. Therefore, 1
(10 lM) and BoNT A (1.0 lg) were added directly to Neuro-
2a cells and irradiated for 4 h at 37 C (Fig. 4). Gratifyingly,
in this scenario, 1 was still able to provide a signiﬁcant amount
of protection (Fig. 4A, lane 8). These data highly suggest that 1
is able to intracellularly mediate BoNT protection as it is antic-
ipated that within the time of the irradiation, functional toxin
would be taken up by the cells into endosomal compartments
[23]. Furthermore, cells that were irradiated in the presence of
riboﬂavin alone (Fig. 4A, lanes 5 and 6) showed no enhanced
cytotoxicity over control cells.
Analogous to these studies, photodynamic therapy (PDT)
has emerged as an extremely promising treatment for a num-
ber of ophthalmic, dermatological, cardiovascular, and uro-
logical diseases, as well as a wide range of cancers [24].
Approved forms of this technology, including Photofrin and
Visudyne, rely on sensitizer activation by a laser light source
that can be delivered directly to the target site [25,26]. The
compilation of these results strongly suggests that the lethal ef-
fects of botulinum neurotoxin can be signiﬁcantly bluntedusing PDT. The use of a dietary vitamin in botulism PDT is
a clear strength of our method, however, further study is re-
quired to determine if more eﬃcient sensitizers are necessary
for in vivo eﬃcacy. Although the intent of this study was the
development of a generic prophylaxis not limited to the treat-
ment of only one BoNT serotype, the speciﬁcity of this ap-
proach could be readily extended using BoNT-speciﬁc
reagents such as antibodies. Such explorations into the scope
of this phenomenon are underway and will be reported in
due course.
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